PDS Biotechnology
PDSB
72 hedge funds and large institutions have $30.2M invested in PDS Biotechnology in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 15 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
2.6% less ownership
Funds ownership: 27.11% → 24.51% (-2.6%)
6% less funds holding
Funds holding: 77 → 72 (-5)
28% less capital invested
Capital invested by funds: $42M → $30.2M (-$11.8M)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
58% less call options, than puts
Call options by funds: $635K | Put options by funds: $1.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$423K |
| 3 |
Goldman Sachs
New York
|
+$402K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$310K |
| 5 |
Jane Street
New York
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$1.99M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.99M |
| 3 |
Two Sigma Advisers
New York
|
-$542K |
| 4 |
Morgan Stanley
New York
|
-$502K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$407K |
PDSB Hedge Fund Activity: Q1 2024 in Review
72 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2024, worth a combined $30.2M — down 28% from $42M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PDSB and 10 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 23 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.21M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $1.99M sold.
- 72 institutional investors held PDS Biotechnology (PDSB) as of Q1 2024, down from 77 in Q4 2023.
- Funds reported $30.2M of PDS Biotechnology stock for Q1 2024, down 28% quarter-over-quarter.
- 10 funds opened new PDS Biotechnology positions in Q1 2024 and 15 closed out, a net change of -5 holders.
- The largest PDS Biotechnology buyer in Q1 2024 was Renaissance Technologies, an estimated $1.21M added.
- The largest PDS Biotechnology seller in Q1 2024 was Jefferies Financial Group, an estimated $1.99M sold.
Based on aggregated 13F filings for Q1 2024.